# Titanium Dioxide Promotes the Growth and Aggregation of Calcium Phosphate and Monosodium Urate Mixed Crystals

**Authors:** Onyebuchi C. Ukaeje, Bidhan C. Bandyopadhyay

PMC · DOI: 10.3390/cryst14010011 · 2024-01-29

## TL;DR

This study shows that titanium dioxide nanoparticles help grow and stabilize crystals linked to gout, raising health concerns.

## Contribution

The study reveals a novel role of titanium dioxide in promoting mixed crystal growth and reducing their dissolution.

## Key findings

- TNPs facilitate the growth and co-aggregation of calcium phosphate and monosodium urate crystals.
- Higher TNP concentrations reduce the dissolution rate of these crystals in the presence of hydroxycitrate.
- TNPs stabilize mixed CaP+MSU crystals, potentially contributing to gout disease progression.

## Abstract

The increased utilization of titanium dioxide (TiO2) nanoparticles (TNPs) in various industrial and consumer products has raised concerns regarding its harmful effect due to its accumulation within the different systems of the human body. Here, we focused on the influence of TNPs on the growth and aggregation of two crucial crystalline substances, calcium phosphate (CaP) and monosodium urate (MSU), particularly its implications in gout disease. In this study, we adopted microscopic techniques and generated kinetic models to examine the interactions between TNPs, CaP and MSU, and crystallization, under controlled laboratory conditions. Our findings reveal that TNPs not only facilitate the growth of these crystals but also promote their co-aggregations. Crystal dissolution kinetics also exhibit that an increase in TNPs concentration corresponds to a reduction in the dissolution rate of CaP and MSU crystals in presence of the dissoluting agent hydroxycitrate (Hcit). These observations suggest that TNPs can stabilize CaP+MSU mixed crystals, which underscores the significance of TNPs’ exposure in the pathogenesis of gout disease.

## Linked entities

- **Chemicals:** titanium dioxide (PubChem CID 26042), calcium phosphate (PubChem CID 24456), monosodium urate (PubChem CID 23690430), hydroxycitrate (PubChem CID 123908)
- **Diseases:** gout (MONDO:0005393)

## Full-text entities

- **Genes:** IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}
- **Diseases:** CPPD deposition (MESH:D002805), inflammatory arthritis (MESH:D001168), Gout (MESH:D006073), aseptic loosening (MESH:D011475), joint damage (MESH:D007592), osteoporosis (MESH:D010024), injury to people or property (MESH:C000719191), MSU (MESH:C562377), CaP (MESH:D002128), inflammatory (MESH:D007249), pain (MESH:D010146)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10824510/full.md

---
Source: https://tomesphere.com/paper/PMC10824510